NASDAQ:NVCR NovoCure (NVCR) Stock Forecast, Price & News $48.66 +1.66 (+3.53%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$45.69▼$48.9250-Day Range$47.00▼$82.5152-Week Range$45.69▼$120.03Volume4.78 million shsAverage Volume1.38 million shsMarket Capitalization$5.17 billionP/E RatioN/ADividend YieldN/APrice Target$72.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability NovoCure MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside48.0% Upside$72.00 Price TargetShort InterestBearish7.70% of Shares Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment-0.34Based on 25 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.92) to ($2.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector773rd out of 980 stocksSurgical & Medical Instruments Industry77th out of 98 stocks 3.1 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $72.00, NovoCure has a forecasted upside of 48.0% from its current price of $48.66.Amount of Analyst CoverageNovoCure has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.70% of the outstanding shares of NovoCure have been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in NovoCure has recently increased by 5.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 2.0 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for NovoCure this week, compared to 4 articles on an average week.Search Interest19 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 138% compared to the previous 30 days.MarketBeat Follows10 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.67% of the stock of NovoCure is held by insiders.Percentage Held by Institutions78.42% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.92) to ($2.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -36.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -36.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 11.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NovoCure (NASDAQ:NVCR) StockNovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.Read More Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Stock News HeadlinesJune 8, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Rating Increased to Neutral at WedbushJune 8, 2023 | msn.comWedbush Upgrades NovoCure (NVCR)June 8, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.June 8, 2023 | msn.comPiper Sandler Maintains NovoCure (NVCR) Neutral RecommendationJune 7, 2023 | benzinga.comLooking At NovoCure's Recent Unusual Options ActivityJune 7, 2023 | msn.comNovoCure upgraded at Wedbush citing balanced risk-reward setupJune 7, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Given New $62.00 Price Target at Piper SandlerJune 7, 2023 | americanbankingnews.comHC Wainwright Lowers NovoCure (NASDAQ:NVCR) Price Target to $85.00June 8, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!June 7, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCRJune 7, 2023 | msn.comWhy did NovoCure stock crash today? TTFields dataJune 7, 2023 | msn.comTruist Securities Reiterates NovoCure (NVCR) Prior RecommendationJune 7, 2023 | msn.comHC Wainwright & Co. Reiterates NovoCure (NVCR) Prior RecommendationJune 6, 2023 | msn.comNovoCure: Misunderstood Lung Cancer Data Creates Enormous Buy OpportunityJune 6, 2023 | finance.yahoo.comNovocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining DoubtsJune 6, 2023 | msn.comHot Stocks: COIN falls as SEC files suit; GTLB gains on earnings; LAZR rises; NVCR slidesJune 6, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for NovoCureJune 6, 2023 | finance.yahoo.comWhy NovoCure Stock Is Crashing TodayJune 6, 2023 | reuters.comNovocure's lung cancer device extends survival in late-stage studyJune 6, 2023 | msn.comNovocure, Zai Lab post Phase 3 data for electric fields device in lung cancerJune 1, 2023 | finanznachrichten.deNovocure Pledges $3 Million to Conquer Cancer, the ASCO Foundation, to Support Cancer Research and EducationJune 1, 2023 | finance.yahoo.comNVCR - NovoCure LimitedJune 1, 2023 | finance.yahoo.comNovocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and EducationMay 19, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Lifted to Overweight at Wells Fargo & CompanyMay 19, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Receives $84.83 Consensus Target Price from BrokeragesMay 18, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Research Coverage Started at StockNews.comMay 16, 2023 | msn.comWells Fargo Upgrades NovoCure (NVCR)See More Headlines NVCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Company Calendar Last Earnings5/04/2023Today6/08/2023Next Earnings (Estimated)7/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,320Year FoundedN/APrice Target and Rating Average Stock Price Forecast$72.00 High Stock Price Forecast$104.00 Low Stock Price Forecast$46.00 Forecasted Upside/Downside+73.3%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,530,000.00 Net Margins-26.98% Pretax Margin-24.96% Return on Equity-32.03% Return on Assets-11.99% Debt Debt-to-Equity Ratio1.31 Current Ratio7.32 Quick Ratio7.11 Sales & Book Value Annual Sales$537.84 million Price / Sales9.61 Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book11.59Miscellaneous Outstanding Shares106,210,000Free Float100,187,000Market Cap$5.17 billion OptionableOptionable Beta0.80 Key ExecutivesAsaf DanzigerChief Executive Officer & DirectorWilhelmus C. M. GroenhuysenChief Operating OfficerAshley CordovaChief Financial OfficerMoshe GiladiChief Science OfficerPiet HinoulSenior Vice President & Head-MedicalKey CompetitorsMerit Medical SystemsNASDAQ:MMSIICU MedicalNASDAQ:ICUIHaemoneticsNYSE:HAEGlobus MedicalNYSE:GMEDInari MedicalNASDAQ:NARIView All CompetitorsInsiders & InstitutionsEP Wealth Advisors LLCBought 5,695 shares on 6/5/2023Ownership: 0.005%Macquarie Group Ltd.Sold 57,955 shares on 6/1/2023Ownership: 0.021%ProShare Advisors LLCSold 2,738 shares on 5/26/2023Ownership: 0.007%Ameriprise Financial Inc.Sold 1,218 shares on 5/22/2023Ownership: 0.009%New York State Common Retirement FundSold 87,571 shares on 5/18/2023Ownership: 0.119%View All Insider TransactionsView All Institutional Transactions NVCR Stock - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price forecast for 2023? 7 Wall Street analysts have issued 1-year price objectives for NovoCure's stock. Their NVCR share price forecasts range from $46.00 to $104.00. On average, they anticipate the company's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2023? NovoCure's stock was trading at $73.35 on January 1st, 2023. Since then, NVCR shares have decreased by 33.7% and is now trading at $48.66. View the best growth stocks for 2023 here. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings data on Thursday, May, 4th. The medical equipment provider reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.14. The medical equipment provider had revenue of $122.20 million for the quarter, compared to analyst estimates of $127.93 million. NovoCure had a negative net margin of 26.98% and a negative trailing twelve-month return on equity of 32.03%. The company's revenue for the quarter was down 11.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) earnings per share. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), First Trust Indxx Medical Devices ETF (MDEV), Strategas Global Policy Opportunities ETF (SAGP), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and BlackRock Future Health ETF (BMED). What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). What is NovoCure's stock symbol? NovoCure trades on the NASDAQ under the ticker symbol "NVCR." Who are NovoCure's major shareholders? NovoCure's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.88%), Baillie Gifford & Co. (8.10%), BlackRock Inc. (7.84%), Price T Rowe Associates Inc. MD (2.50%), Geode Capital Management LLC (1.32%) and Credit Suisse AG (0.83%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NovoCure's stock price today? One share of NVCR stock can currently be purchased for approximately $48.66. How much money does NovoCure make? NovoCure (NASDAQ:NVCR) has a market capitalization of $5.17 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. How many employees does NovoCure have? The company employs 1,320 workers across the globe. How can I contact NovoCure? NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com. This page (NASDAQ:NVCR) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.